hVIVO plc announces a breakthrough in identifying biomarkers for respiratory infections, published in Nature Communications, advancing diagnostics and patient care...
hVIVO plc, a leader in human challenge trials, announces positive results for Enanta Pharmaceuticals' RSV antiviral candidate EDP-323 in a recent study...
hVIVO plc (LON:HVO), a leading CRO in infectious and respiratory disease research, will release its interim results for H1 2024 on 10 September 2024...
hVIVO plc (LON:HVO), a leading CRO specializing in infectious and respiratory disease products, reports a robust 30.6% revenue growth for H1 2024, driven by strong operational performance...
hVIVO to conduct a major Phase 2b field study on an influenza drug, enrolling 1,000 volunteers at its expanded Plumbers Row site, supporting future growth...
Discover the latest updates from hVIVO plc, a leading CRO specialising in infectious disease testing through human challenge trials. Join their AGM on 13 May 2024...
hVIVO plc, a leading CRO in infectious disease trials, announces strong financial results and operational achievements for 2023, setting the stage for continued growth...
hVIVO plc, the world leader in infectious disease testing, has reported double-digit revenue growth and improved EBITDA margins and cash for 2023. The company expects to pay an annual dividend and has set a new revenue target of £100 million by 2028. The growing orderbook and high revenue visibility indicate a strong market position...
hVIVO plc announces a breakthrough in identifying biomarkers for respiratory infections, published in Nature Communications, advancing diagnostics and patient care...
hVIVO plc, a leader in human challenge trials, announces positive results for Enanta Pharmaceuticals' RSV antiviral candidate EDP-323 in a recent study...
hVIVO plc (LON:HVO), a leading CRO in infectious and respiratory disease research, will release its interim results for H1 2024 on 10 September 2024...
hVIVO plc (LON:HVO), a leading CRO specializing in infectious and respiratory disease products, reports a robust 30.6% revenue growth for H1 2024, driven by strong operational performance...
hVIVO to conduct a major Phase 2b field study on an influenza drug, enrolling 1,000 volunteers at its expanded Plumbers Row site, supporting future growth...
Discover the latest updates from hVIVO plc, a leading CRO specialising in infectious disease testing through human challenge trials. Join their AGM on 13 May 2024...
hVIVO plc, a leading CRO in infectious disease trials, announces strong financial results and operational achievements for 2023, setting the stage for continued growth...
hVIVO plc, the world leader in infectious disease testing, has reported double-digit revenue growth and improved EBITDA margins and cash for 2023. The company expects to pay an annual dividend and has set a new revenue target of £100 million by 2028. The growing orderbook and high revenue visibility indicate a strong market position...
